drugset / Trial / NCT00211224

Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)

NCT00211224 ↗

RandomizedParallel-groupDouble-blindTreatment

Summary

NNIPPS is a clinical trial of riluzole (a drug previously shown to slow down the rate of progression og amyotrophic lateral sclerosis-ALS; Lou Gehrig's disease) involving nearly 800 people diagnosed with the 'parkinson plus' syndromes of multiple system atrophy (MSA) and progressive supranuclear plasy (PSP). In addition to showing whether riluzole is helpful in MSA and PSP, NNIPPS will improve criteria for making an accurate and early diagnosis, for assessing the rate of progression, and will advance understanding of the biology of these disabling and progressive neurodegenerative diseases.

Timeline

Start
2000-04
Primary completion
—
Completion
2004-11

Outcome

Missed primary endpoint

paper There was no evidence of a drug effect on survival in the PSP or MSA strata PMID 19029129 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Riluzole Small molecule 200 mg —